90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

Vincent J. Picozzi, Ramesh K. Ramanathan, Maeve A. Lowery, Allyson J. Ocean, Edith P. Mitchel, Bert H. O'neil, Michael J. Guarino, Paul R. Conkling, Steven J. Cohen, Nathan Bahary, Richard C. Frank, Tomislav Dragovich, Benjamin B. Bridges, Fadi S. Braiteh, Alexander N. Starodub, Fa Chyi Lee, Thomas E. Gribbin, Donald A. Richards, Marie Lee, Ronald L. KornNeeta Pandit-Taskar, Stanley J. Goldsmith, Charles M. Intenzo, Arif Sheikh, Timothy C. Manzone, Heather Horne, Robert M. Sharkey, William A. Wegener, Eileen M. O'reilly, David M. Goldenberg, Daniel D. Von Hoff

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Fingerprint

Dive into the research topics of '90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies'. Together they form a unique fingerprint.

Medicine & Life Sciences